Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.85 |
| ▸ | HTT | P42858 | 2/20 | 0.84 |
| ▸ | RAB9A | P51151 | 1/20 | 0.84 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5365677 | 0.84 | ALDH1A1 (0.66) | ALDH1A1HTTRAB9AHSD17B10 | |
| SCHEMBL5357034 | 0.82 | ALDH1A1 (0.63) | ALDH1A1HTTRAB9AHSD17B10 | |
| SCHEMBL13975009 | 0.82 | ALDH1A1 (0.77) | ALDH1A1HTTRAB9ANPSR1KDM4E | |
| SCHEMBL5381728 | 0.82 | ALDH1A1 (0.63) | ALDH1A1HTTRAB9AHSD17B10 | |
| SCHEMBL3516960 | 0.81 | ALDH1A1 (0.74) | ALDH1A1HTTRAB9ANPSR1KDM4E | |
| SCHEMBL9010473 | 0.80 | ALDH1A1 (0.79) | ALDH1A1HTTRAB9ANPSR1KDM4E | |
| SCHEMBL4158508 | 0.80 | ALDH1A1 (0.79) | ALDH1A1HTTRAB9ANPSR1KDM4E | |
| SCHEMBL8699832 | 0.80 | ALDH1A1 (0.73) | ALDH1A1HTTRAB9ANPSR1KDM4E | |
| SCHEMBL7934013 | 0.80 | ALDH1A1 (0.79) | ALDH1A1HTTRAB9ANPSR1KDM4E | |
| SCHEMBL15750820 | 0.79 | ALDH1A1 (0.84) | ALDH1A1HTTRAB9ANPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814885-A2 | NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006073610-A2 | NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | HPSE, ENGASE, UGCG | ALDH1A1 2651/4885HTT 1217/4885RAB9A 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.